Despite therapy with complement inhibitors, half of individuals with paroxysmal nocturnal hemoglobinuria (PNH) develop breakthrough hemolysis, or BTH —…
Articles by Patricia Inacio PhD
Paroxysmal nocturnal hemoglobinuria (PNH) was identified as the likely cause of a stroke in a young man, according to…
Epysqli (SB12), a biosimilar of Soliris (eculizumab), is comparable in safety and efficacy for Asian and non-Asian patients with…
Patients with paroxysmal nocturnal hemoglobinuria (PNH) in 53 countries with limited access to life-saving treatments will be able to…
In rare cases, acute kidney injury may be sign of paroxysmal nocturnal hemoglobinuria (PNH), as described in a recent…
Treatment with Ultomiris (ravulizumab) enabled paroxysmal nocturnal hemoglobinuria (PNH) patients to achieve the same level of physical and…
A young woman with paroxysmal nocturnal hemoglobinuria (PNH) developed neutropenic enterocolitis (NEC), a severe and life-threatening complication, after receiving…
Increasing dosing of Empaveli (pegcetacoplan) followed by co-administering Soliris (eculizumab) effectively managed acute red blood cell destruction in…
A pregnant woman with paroxysmal nocturnal hemoglobinuria (PNH) and an inherited blood clotting disorder had a successful and uneventful…
Epysqli (SB12), a biosimilar of Soliris (eculizumab), is as effective as the reference therapy in reducing the need for…